Article
Terminal Sterilization vs. Aseptic Fill-Finish — CMC Decision Framework and Regulatory Implications
FDA's 2004 Aseptic Processing Guidance states that terminal sterilization should be used whenever possible. Your pharmaceutical development section is where you document when it is not possible, and…
XGene Articles & Analysis
Evidence-led analysis for decisions that matter.
Senior-authored regulatory, CMC, GMP, quality, and inspection analysis designed for practical use—not passive reading.
01SignalSource evidence
02InterpretTechnical judgment
03ApplyDecision pathway
Publication library
Keep moving from evidence to decision.
Article
Terminal Sterilization vs. Aseptic Fill-Finish — CMC Decision Framework and Regulatory Implications
FDA's 2004 Aseptic Processing Guidance states that terminal sterilization should be used whenever possible. Your pharmaceutical development section is where you document when it is not possible, and…
Article
Aseptic Process Validation — FDA 2004 Guidance and the Media Fill Program That Survives Pre-Approval Inspection
Zero contaminated units across three media fills is the FDA aseptic process validation acceptance criterion. Arriving at that result starts with the media fill design, not with the…
Article
Endotoxin Control in Injectables — LAL Method Validation, Limits Calculation, and the FDA Deficiency Pattern
FDA's endotoxin limit formula is four variables: the threshold K, the maximum hourly dose M, and the arithmetic result EL = K/M.
Article
Sterility Assurance for Injectable Drug Products — Container Closure Integrity, SAL 10^-6, and the CMC Evidence Package
USP is the sterility test. It is not your sterility assurance program.
Article
Pediatric OSD CMC — Taste Masking, Age-Appropriate Formulation, and the EMA-FDA Pediatric CMC Framework
FDA approved your adult IR tablet. Your pediatric study plan commits to a mini-tablet formulation for patients aged 6 and older. Now your CMC team must demonstrate that…
Article
Orally Disintegrating Tablets and Novel Oral Delivery Systems — CMC for Patient-Centric Formulations
The FDA defines an ODT as a tablet that disintegrates in about 30 seconds on the tongue. That 30-second criterion is the CMC specification your ODT NDA or…
Article
Semi-Solid and Topical Dosage Forms — CMC Considerations for Semisolid Drug Products Under FDA Q1-Q3 Guidance
Q1 and Q2 sameness gets your topical ANDA accepted for filing. Q3 microstructure equivalence is what gets it approved. If your Q3 data package is a single-point viscosity…
Article
Scale-Up and Post-Approval Changes for OSD — SUPAC-IR-MR Guidelines Applied to Real Manufacturing Changes
The SUPAC classification matrix is 30 years old. It is also the framework FDA will use to evaluate your CBE-30 filing for the 5× batch size scale-up you…
Article
Generic Drug CMC — ANDA Strategy, OGD Deficiency Patterns, and the Abbreviated Approval Package
The GDUFA goal of a 90% on-time first-cycle action rate for complete ANDAs is the performance standard for OGD — not for generic sponsors. A first-cycle approval requires…
Article
Bioequivalence and OSD CMC — BCS Classification, In Vivo Data, and the NDA CMC Interface
The bioequivalence study and the CMC dossier are written by different teams, reviewed by different FDA divisions, and filed in different parts of the NDA — but they…
Article
Container Closure for OSD — HDPE Bottles, Blisters, and the Functional Suitability Evidence Package
Selecting a container closure system for an oral solid dosage form is a stability decision, not a packaging decision. For a moisture-sensitive tablet where degradation accelerates sharply with…
Article
OSD Stability — ICH Q1 Applied to Moisture-Sensitive and Light-Sensitive Oral Drug Products
The 36-month shelf life on your oral tablet is a statistical prediction, not a measured fact — and the quality of that prediction depends entirely on whether the…
Read with purpose
Every analysis should make the next move clearer.
- 01ReadUnderstand the technical argument.
- 02TraceFollow evidence and regulatory context.
- 03CompareExplore related XGene intelligence.
- 04ActConnect the issue to a practical pathway.